Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
372
mi
from 91732
Davis, CA
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
372
mi
from 91732
Davis, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
355
mi
from 91732
San Francisco, CA
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
2281
mi
from 91732
Washington,
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
2315
mi
from 91732
Fort Lauderdale, FL
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
2261
mi
from 91732
Vero Beach, FL
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
2261
mi
from 91732
Vero Beach, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
2304
mi
from 91732
West Palm Beach, FL
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
2304
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
1960
mi
from 91732
Berkley, MI
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
1960
mi
from 91732
Berkley, MI
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
2423
mi
from 91732
Newark, NJ
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
2423
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
690
mi
from 91732
Santa Fe, NM
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
690
mi
from 91732
Santa Fe, NM
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated:  11/30/2014
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Status: Enrolling
Updated: 11/30/2014
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Reducing HIV Stigma for African American Women
Reducing HIV Stigma to Improve Health Outcomes for African-American Women
Status: Enrolling
Updated:  12/1/2014
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Reducing HIV Stigma for African American Women
Reducing HIV Stigma to Improve Health Outcomes for African-American Women
Status: Enrolling
Updated: 12/1/2014
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Reducing HIV Stigma for African American Women
Reducing HIV Stigma to Improve Health Outcomes for African-American Women
Status: Enrolling
Updated:  12/1/2014
Northwestern University (NU)
1729
mi
from 91732
Chicago, IL
Reducing HIV Stigma for African American Women
Reducing HIV Stigma to Improve Health Outcomes for African-American Women
Status: Enrolling
Updated: 12/1/2014
Northwestern University (NU)
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART
Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed a Single Tablet Regimen (STR) Versus Multi Tablet Regimen (MTR).
Status: Enrolling
Updated:  12/17/2014
Triple O Research Institute, P.A.
2304
mi
from 91732
West Palm Beach, FL
Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART
Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed a Single Tablet Regimen (STR) Versus Multi Tablet Regimen (MTR).
Status: Enrolling
Updated: 12/17/2014
Triple O Research Institute, P.A.
2304
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects
Status: Enrolling
Updated:  12/18/2014
ACRIA
213
mi
from 91732
New York, NY
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects
Status: Enrolling
Updated: 12/18/2014
ACRIA
213
mi
from 91732
New York, NY
Click here to add this to my saved trials
Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls
Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls
Status: Enrolling
Updated:  1/5/2015
Special Immunology Unit
2036
mi
from 91732
Cleveland, OH
Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls
Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls
Status: Enrolling
Updated: 1/5/2015
Special Immunology Unit
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults
Status: Enrolling
Updated:  1/20/2015
Magee-Womens Hospital of UPMC
2121
mi
from 91732
Pittsburgh, PA
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults
Status: Enrolling
Updated: 1/20/2015
Magee-Womens Hospital of UPMC
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects
Status: Enrolling
Updated:  2/2/2015
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects
Status: Enrolling
Updated: 2/2/2015
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects
Status: Enrolling
Updated:  2/2/2015
University of Texas Health Science Center at Houston
1352
mi
from 91732
Houston, TX
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects
Status: Enrolling
Updated: 2/2/2015
University of Texas Health Science Center at Houston
1352
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Metformin for HIV Inflammation
Open-Label, Randomized, 24-Week Pilot Study of Metformin vs Observation for Persistent Immune Activation in Chronic HIV Infection
Status: Enrolling
Updated:  3/3/2015
Hawaii Center for AIDS
2570
mi
from 91732
Honolulu, HI
Metformin for HIV Inflammation
Open-Label, Randomized, 24-Week Pilot Study of Metformin vs Observation for Persistent Immune Activation in Chronic HIV Infection
Status: Enrolling
Updated: 3/3/2015
Hawaii Center for AIDS
2570
mi
from 91732
Honolulu, HI
Click here to add this to my saved trials
HIV Medication Adherence in Underserved Populations
A Cognitive Rehabilitation Program to Promote Treatment Adherence for Individuals Who Are HIV Positive With Mild Neurocognitive Difficulties
Status: Enrolling
Updated:  3/18/2015
Cedars-Sinai Medical Center
13
mi
from 91732
Los Angeles, CA
HIV Medication Adherence in Underserved Populations
A Cognitive Rehabilitation Program to Promote Treatment Adherence for Individuals Who Are HIV Positive With Mild Neurocognitive Difficulties
Status: Enrolling
Updated: 3/18/2015
Cedars-Sinai Medical Center
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated:  4/23/2015
Keck School of Medicine - LAUSC
13
mi
from 91732
Los Angeles, CA
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated: 4/23/2015
Keck School of Medicine - LAUSC
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated:  4/23/2015
SCFLD Hepatology Diagnostic Research Laboratory
2322
mi
from 91732
Miami, FL
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated: 4/23/2015
SCFLD Hepatology Diagnostic Research Laboratory
2322
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated:  4/23/2015
Minneapolis Medical Research Foundation
1509
mi
from 91732
Minneapolis, MN
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated: 4/23/2015
Minneapolis Medical Research Foundation
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated:  4/23/2015
NYC Dept Health & Mental Hygiene
2351
mi
from 91732
New York, NY
Rapid Diagnostics for HIV and Hepatitis
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Status: Enrolling
Updated: 4/23/2015
NYC Dept Health & Mental Hygiene
2351
mi
from 91732
New York, NY
Click here to add this to my saved trials
PRO 140 for Human Immunodeficiency Virus
A Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Observed Systemic, Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Recreational Drug Users With Viral Rebound and Poor Adherence to the Previous Antiretroviral Regimen
Status: Enrolling
Updated:  5/7/2015
Drexel University
2375
mi
from 91732
Phildadelphia, PA
PRO 140 for Human Immunodeficiency Virus
A Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Observed Systemic, Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Recreational Drug Users With Viral Rebound and Poor Adherence to the Previous Antiretroviral Regimen
Status: Enrolling
Updated: 5/7/2015
Drexel University
2375
mi
from 91732
Phildadelphia, PA
Click here to add this to my saved trials
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Status: Enrolling
Updated:  5/26/2015
Stanford University AIDS Clinical Trials Unit
326
mi
from 91732
Palo Alto, CA
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Status: Enrolling
Updated: 5/26/2015
Stanford University AIDS Clinical Trials Unit
326
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
HIV Risk and Prevention in Women
Collaborative Biosocial Research on HIV Risk and Prevention in Women
Status: Enrolling
Updated:  6/2/2015
University of Oklahoma
1165
mi
from 91732
Oklahoma City, OK
HIV Risk and Prevention in Women
Collaborative Biosocial Research on HIV Risk and Prevention in Women
Status: Enrolling
Updated: 6/2/2015
University of Oklahoma
1165
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
21
mi
from 91732
Beverly Hills, CA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
21
mi
from 91732
Beverly Hills, CA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
355
mi
from 91732
San Francisco, CA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
19
mi
from 91732
West Hollywood, CA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
19
mi
from 91732
West Hollywood, CA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
817
mi
from 91732
Denver, CO
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
817
mi
from 91732
Denver, CO
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2281
mi
from 91732
Washington,
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2314
mi
from 91732
Ft Lauderdale, FL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2314
mi
from 91732
Ft Lauderdale, FL
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2321
mi
from 91732
Miami, FL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2121
mi
from 91732
Safety Harbor, FL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2121
mi
from 91732
Safety Harbor, FL
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2261
mi
from 91732
Vero Beach, FL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2261
mi
from 91732
Vero Beach, FL
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1978
mi
from 91732
Macon, GA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1978
mi
from 91732
Macon, GA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials